Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.

<p>Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.</p>

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.

<p>Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.</p>

Listen to top interviews from Bloomberg News.

Bloomberg Talks

Lilly CEO Talks Fighting Cancer and Obesity, Drug Pricing

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/4533335d-1e9a-4d60-ab8b-b2640108d199/transcript

Advertisement